United Therapeutics (UTHR) Accumulated Expenses (2016 - 2025)
United Therapeutics (UTHR) has disclosed Accumulated Expenses for 17 consecutive years, with $480.9 million as the latest value for Q4 2025.
- Quarterly Accumulated Expenses rose 42.07% to $480.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $480.9 million through Dec 2025, up 42.07% year-over-year, with the annual reading at $480.9 million for FY2025, 42.07% up from the prior year.
- Accumulated Expenses hit $480.9 million in Q4 2025 for United Therapeutics, up from $338.5 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $480.9 million in Q4 2025 to a low of $170.8 million in Q4 2021.
- Historically, Accumulated Expenses has averaged $301.7 million across 5 years, with a median of $292.4 million in 2023.
- Biggest five-year swings in Accumulated Expenses: decreased 6.62% in 2021 and later skyrocketed 42.07% in 2025.
- Year by year, Accumulated Expenses stood at $170.8 million in 2021, then soared by 32.2% to $225.8 million in 2022, then grew by 29.5% to $292.4 million in 2023, then increased by 15.77% to $338.5 million in 2024, then surged by 42.07% to $480.9 million in 2025.
- Business Quant data shows Accumulated Expenses for UTHR at $480.9 million in Q4 2025, $338.5 million in Q4 2024, and $292.4 million in Q4 2023.